Dr. Paul Wheatley-Price is Associate Professor in the Department of Medicine at the University of Ottawa, and a medical oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary.
He is the medical oncology lead for the lung cancer disease site group in Ottawa, and is the current Program Director for the medical oncology residency training program.
From 2016 - 2021 Dr. Wheatley-Price served as President of Lung Cancer Canada, and he remains active in lung cancer advocacy.
Dr. Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994 - 1997). He received specialist medical oncology training in Wellington, New Zealand, in London at the Royal Free Hospital, Guy’s and St. Thomas’ Hospitals and St. George’s Hospital, and as a Fellow in Lung Cancer Research at Princess Margaret Cancer Centre in Toronto.
He has been in Ottawa since 2009.
Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec and a member of the Centre des maladies du sein. She is a clinical researcher in the oncology axis of the CHU de Québec research center.
She obtained her M.D. from Laval University in 1997 and completed her fellowship in breast cancer at Mount Sinai Hospital in 2005, where she also obtained a Master's degree in clinical epidemiology from the University of Toronto. She has worked at CHU de Québec since 2006. Dr. Lemieux is a member of the Quality of Life and Breast Cancer Committee of the CCTG Clinical Trials Group. She is also on the governance committee of the Quebec breast metastatic registry. Her research activities focus on breast cancer, quality of life, treatment toxicity and use of real life data.
Dr. Powell graduated from MUN medical school in 2004 and Internal Medicine training in 2007. She went on to complete Medical Oncology training at the University of Ottawa in 2009 and then returned to Newfoundland to work at the Dr. H. Bliss Murphy Cancer Center. Her clinical interests include breast and colon cancer as well as sarcoma. Dr. Powell is the program director for the Medical Oncology training program at Memorial and is an Associate Professor with the Discipline of Oncology. She joined the executive of CAMO in 2022 as the Secretary-Treasurer and also Co-Chairs the Atlantic Canada Oncology Group.
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a GI medical oncologist at BC Cancer in Vancouver, Canada. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and as the President of the Canadian Association of Medical Oncologists
Dr. Heng is the Division Head of Medical Oncology at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and trained at the BC Cancer Agency and Cleveland Clinic Taussig Cancer Institute. He has a Masters of Public Health from Harvard University and has a keen interest in outcomes, prognostic factors and clinical trials research in kidney, bladder, prostate and testicular cancers.
Dr. Juergens completed a fellowship in medical oncology with a focus on thoracic malignancies at the Johns Hopkins Medical Institute. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011.
Dr. Juergens’ clinical expertise is in lung cancer. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. Her passion is expanding knowledge and access to clinical trials. She is a member of the Early Therapy Advisory Committee and member of the Lung Disease Site Group Executive in the Canadian Cancer Trials Group.
She chaired the Lung Cancer Disease Site Team at the Juravinski Cancer Centre from 2013-2024. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute and the Centre for Discovery and Cancer Research at McMaster University. She is a proud teacher and mentor and winner of the 2024 Women in Cancer Mentor of the Year. She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. Her efforts were acknowledged by the 2024 Canadian Association of Medical Oncologists Humanitarian Award.
David Cescon MD, PhD, is a breast Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre. His research integrates laboratory and clinical studies, focused on the identification of breast cancer therapeutic vulnerabilities and determinants of drug response and resistance. He serves in a number of co-operative group roles, including as the incoming chair of the Canadian Cancer Trials Group IND committee, co-chair of the NCTN Core Correlative Sciences Committee, and member of Breast International Group and NCI BIO Working Groups.
